title: Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?
abstract: Aberrant activity of tyrosine kinases has been proved to be associated with multiple diseases including fibrotic diseases. Tyrosine kinases inhibitors (TKIs) might be a novel approach to transform the anti-fibrotic treatment. However, both beneficial and adverse effects are observed by researchers when using these TKIs in either preclinical animal models or patients with hepatic fibrosis. Since hepatotoxicity of TKIs is the leading cause for drug withdrawals thus limits its application in anti-fibrosis, not only efficacy but also safety of TKIs should be paid great concerns. It has been observed in a few studies that TKIs could induce relatively high rate of hepatic biochemical markers elevations and even result in liver failure. Fortunately, several strategies have been adopt to handle with the hepatotoxicity. Accumulating evidences suggest that hepatic stellate cells (HSC) play a pivotal role in hepatic fibrogenesis, so it might be a good option to develop selective TKIs specifically targeting HSCs. The present review will briefly summarize the anti-fibrotic mechanism of TKIs, adverse effects of TKIs as well as the novel developed selective delivery of TKIs.
authors: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
authors: Kai
authors: K
authors: Qu
authors: Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
authors: Tian
authors: T
authors: Liu
authors: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.|Department of Surgical Intensive Care Unit (SICU), The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
authors: Ting
authors: T
authors: Lin
authors: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
authors: Xing
authors: X
authors: Zhang
authors: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
authors: Ruixia
authors: R
authors: Cui
authors: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.|Department of Surgical Intensive Care Unit (SICU), The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
authors: Sinan
authors: S
authors: Liu
authors: Department of Geriatric Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
authors: Fandi
authors: F
authors: Meng
authors: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.|Department of Surgical Intensive Care Unit (SICU), The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
authors: Jingyao
authors: J
authors: Zhang
authors: Department of Ultrasound, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
authors: Minghui
authors: M
authors: Tai
authors: Department of Geriatric Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
authors: Yong
authors: Y
authors: Wan
authors: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.|Department of Surgical Intensive Care Unit (SICU), The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
authors: Chang
authors: C
authors: Liu
mesh_terms: D000818:Animals; D055166:Hepatic Stellate Cells / Q000187:drug effects; D006801:Humans; D008099:Liver / Q000187:drug effects; D008103:Liver Cirrhosis / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases
keywords: hepatic fibrosis; hepatotoxicity; tyrosine kinase inhibitors